Johnson & Johnson ( (JNJ) ) has released its Q4 earnings. Here is a breakdown of the information Johnson & Johnson presented to its investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Johnson & Johnson is a diversified healthcare giant renowned for its operations in the pharmaceutical, medical devices, and consumer health sectors, with a strong emphasis on innovation and addressing unmet medical needs.
In its latest earnings report, Johnson & Johnson announced impressive growth metrics for the fourth quarter and full year of 2024. The company reported a fourth-quarter sales increase of 5.3% to $22.5 billion, with an operational growth of 6.7%. The full-year sales rose by 4.3% to $88.8 billion, showcasing the company’s robust financial health and successful strategic initiatives.
Key financial highlights include a full-year earnings per share (EPS) of $5.79 and an adjusted EPS of $9.98. The company also emphasized significant progress in its R&D pipeline, with advancements in treatments for diseases such as multiple myeloma and lung cancer. Additionally, Johnson & Johnson’s MedTech division showed substantial growth, driven by innovations in cardiovascular and general surgery products.
Looking ahead, Johnson & Johnson has issued guidance for 2025, anticipating operational sales growth of 2.5% to 3.5% and an adjusted operational EPS increase of 8.7% at the mid-point. With a solid foundation and a diverse portfolio, the company is well-positioned to continue its trajectory of growth and innovation in the healthcare sector.
